Recent studies indicate that TMED9 overexpression in ovarian cancer correlates with poor overall survival, while in breast cancer, high TMED9 expression is associated with enhanced tumor proliferation and migratory capacity (8, 9). This evidence concerns the gene TMED9 and neoplasm.